(DJ Bolsa)– Novartis said preliminary data from a Phase 3 study showed that treatment with ribociclib Kisqali significantly reduced the risk of cancer recurrence in a broad population of patients with early-stage breast cancer.
The Swiss pharmaceutical giant said on Friday that ribociclib combined with endocrine therapy reduced the risk of cancer recurrence by 25.2% in patients …
Copyright (c) 2020 Dow Jones & Company, Inc.#Novartis #Kisqali #treatment #reduces #risk #breast #cancer #recurrence #Latest
1685758932
2023-06-02 14:03:47
/cloudfront-eu-central-1.images.arcpublishing.com/prisa/ZIVJZVRFYFER5BAUJY46LOJR6Y.jpg)
:format(webp)/cloudfront-us-east-1.images.arcpublishing.com/grupoclarin/EA3NUKZS2NGD5EMMHYM4ZWB6LU.png)
